miR-24-3p as a Modulator of Cardiac Function via Sp1/PI3K Signaling

Study Background and Research Question

Heart failure (HF) remains a major cause of morbidity and mortality worldwide, with myocardial injury and subsequent cardiomyocyte apoptosis and oxidative stress as key pathogenic drivers. MicroRNAs (miRNAs) have emerged as pivotal post-transcriptional regulators in cardiovascular diseases, modulating gene expression networks that control cell survival and function. Among these, miR-24-3p has been implicated in several cardiac pathologies, but its precise molecular targets and mechanistic roles in HF have not been fully defined. The recent study by Zheng et al. addresses this gap by systematically investigating the role of miR-24-3p in doxorubicin-induced HF, with a focus on the Sp1/PI3K signaling axis.

Key Innovation from the Reference Study

The central innovation of this research lies in the identification of a regulatory axis involving miR-24-3p, specificity protein 1 (Sp1), and the phosphoinositide 3-kinase (PI3K) pathway in cardiac dysfunction. By demonstrating that miR-24-3p directly targets Sp1 and thereby modulates PI3K expression, the authors establish a mechanistic link between miRNA regulation and the PI3K/Akt/mTOR signaling pathway—a pathway previously recognized for its roles in cell survival, apoptosis, and metabolism. This axis is shown to be critical in the context of doxorubicin-induced cardiac injury, positioning miR-24-3p as a potential upstream therapeutic target.

Methods and Experimental Design Insights

The investigators employed both in vivo and in vitro models to dissect the functional consequences of miR-24-3p modulation. Heart failure was induced in rats using doxorubicin, a chemotherapeutic agent known to cause cardiotoxicity. Cardiac function was assessed via echocardiography, while histopathological alterations were characterized by hematoxylin-eosin staining. At the cellular level, H9c2 cardiomyocytes were exposed to doxorubicin to model injury. To interrogate the roles of Sp1 and PI3K, specific inhibitors were applied, including a PI3K inhibitor, which in related literature is commonly 2-(4-Morpholinyl)-8-phenyl-4H-l-benzopyran-4-one (LY294002), a potent and reversible class I PI3K inhibitor.

Further, miR-24-3p levels were manipulated through overexpression and silencing constructs. Molecular endpoints included NT-proBNP quantification by ELISA, apoptosis assessment via TUNEL staining, LDH release by colorimetry, and ROS measurement via flow cytometry. Expression of key genes and proteins (miR-24-3p, Sp1, PI3K, Caspase-3) was evaluated by qRT-PCR and Western blotting. The direct interaction between miR-24-3p and the Sp1 3' UTR was confirmed by dual-luciferase reporter assays.

Protocol Parameters

• Doxorubicin-induced HF model: Rats were administered doxorubicin to induce heart failure; H9c2 cells were treated with doxorubicin to mimic cardiomyocyte injury.
• PI3K inhibition: Application of a PI3K inhibitor (e.g., LY294002 at 1–10 μM in cell culture) to assess pathway involvement; duration and concentration selected based on dose-dependent inhibition of PI3K/Akt signaling as described in product information.
• miR-24-3p modulation: Use of overexpression and silencing constructs to delineate miRNA-specific effects on cardiomyocyte viability and pathway activity.
• Sp1 inhibition: Application of Sp1 inhibitor in parallel with PI3K inhibitor to dissect regulatory interdependence.

Core Findings and Why They Matter

The study reveals several important mechanistic insights:

• Doxorubicin treatment in rats led to classical features of HF, including increased left ventricular diameter, reduced ejection fraction, and histological evidence of cardiomyocyte disarray, edema, and necrosis.
• At the molecular level, HF was characterized by increased NT-proBNP, Caspase-3, and miR-24-3p, alongside decreased Sp1 and PI3K expression in both animal and cell models.
• Pharmacological inhibition of Sp1 or PI3K (using inhibitors such as LY294002) exacerbated doxorubicin-induced cardiomyocyte damage, evidenced by further elevations in NT-proBNP, apoptosis, LDH release, ROS production, and miR-24-3p, while further suppressing Sp1 and PI3K expression.
• Overexpression of miR-24-3p worsened cardiac injury, while silencing miR-24-3p reversed these effects, restoring Sp1 and PI3K levels and reducing markers of apoptosis and oxidative stress.
• Dual-luciferase assays confirmed miR-24-3p's direct targeting of Sp1, and reciprocal regulation between Sp1 and PI3K was observed, supporting the existence of a tightly regulated miR-24-3p/Sp1/PI3K axis.

These findings are significant as they identify miR-24-3p not only as a biomarker of cardiac injury but as a functional regulator of the Sp1/PI3K pathway, providing a mechanistic basis for therapeutic targeting in doxorubicin-induced HF.

Comparison with Existing Internal Articles

This study complements and extends the mechanistic landscape outlined in prior research on PI3K/Akt/mTOR signaling and its pharmacological inhibition. For example, recent work on FGFR and PI3K/AKT cross talk in breast cancer highlights the pathway’s relevance beyond oncology, including its role in periostin regulation and fibrotic remodeling. Similarly, advanced mechanistic overviews such as LY294002: Redefining the Translational Research Paradigm and LY294002: Advanced Insights into PI3K Signaling, Fibrosis... discuss how PI3K inhibition by molecules like 2-(4-Morpholinyl)-8-phenyl-4H-l-benzopyran-4-one can dissect signaling in both cancer and fibrotic disease. The current study bridges this knowledge to the cardiovascular domain by showing that PI3K pathway inhibition, while informative mechanistically, can exacerbate cardiac injury in the setting of miR-24-3p upregulation and doxorubicin toxicity. Thus, the findings reinforce the context-dependent outcomes of targeting PI3K and underscore the need for precise modulation strategies in cardiovascular research.

Limitations and Transferability

While the evidence robustly implicates the miR-24-3p/Sp1/PI3K axis in doxorubicin-induced HF, several limitations warrant consideration. The study predominantly utilizes rodent models and rat cardiomyocyte lines, which, while informative, may not fully recapitulate human cardiac pathophysiology. The use of pharmacological inhibitors, including PI3K pathway inhibitors, provides mechanistic clarity but may introduce off-target effects not addressed in this study. Additionally, the interplay between miR-24-3p and other signaling cascades remains to be elucidated, and the therapeutic potential of miR-24-3p modulation in established, chronic HF is yet to be determined. Transferability to human disease and other etiologies of HF therefore requires further validation.

Why this cross-domain matters, maturity, and limitations

The convergence of PI3K/Akt/mTOR signaling research in both oncology and cardiology, as illustrated by the referenced and internal articles, emphasizes the pathway's centrality in cell survival, apoptosis, and tissue remodeling. However, while inhibition of PI3K is often beneficial in cancer models (e.g., ovarian carcinoma, breast cancer), the current cardiac findings highlight that indiscriminate pathway inhibition may be detrimental in the context of acute cardiac injury. This underscores the necessity for domain-specific validation and careful translation of pathway-targeting strategies.

Research Support Resources

For researchers aiming to interrogate the PI3K/Akt/mTOR signaling pathway or model pathway inhibition in vitro, LY294002 (2-(4-Morpholinyl)-8-phenyl-4H-l-benzopyran-4-one, SKU A8250) from APExBIO is a cell-permeable, reversible class I PI3K inhibitor with well-characterized activity profiles. It is suitable for use at 1–10 μM in cell culture and has been extensively utilized for mechanistic dissection in both cardiovascular and oncology research. When modeling the effects of PI3K inhibition on apoptosis, autophagy, and related processes, researchers should consult the product documentation for solubility and storage guidelines to ensure experimental reproducibility.